Amodiaquine for treating malaria

Hematoxicity of amodiaquine in sprague-dawley rats

“…This is in consonance with previous studies[1112] that observed marginal and within normal limits of hematological profile with no agranulocytosis in patients who received AQ treatment. However, this is in contrast with other studies[3] that reported agranulocytosis in adults taking AQ for prophylaxis. The variation observed might be due to the duration of treatment, as cases that reported AQ-induced agranulocytosis were associated with its long-term use as prophylaxis.…”

Hematoxicity of amodiaquine in sprague-dawley rats

“…This is in consonance with previous studies[1112] that observed marginal and within normal limits of hematological profile with no agranulocytosis in patients who received AQ treatment. However, this is in contrast with other studies[3] that reported agranulocytosis in adults taking AQ for prophylaxis. The variation observed might be due to the duration of treatment, as cases that reported AQ-induced agranulocytosis were associated with its long-term use as prophylaxis.…”

Artemisinin-induced delayed hemolysis after administration of artesunate and artesunate-amodiaquine in malaria-free Wistar rats

“…Amodiaquine is implicated as a cause of neutropenia, which is characterized by a decrease in granular white blood cells after prolonged use for prophylaxis (Olliaro and Mussano, 2003). Our findings are in consonance with other reported animals studies (Omotuyi, 2008) and that observed in human treated with amodiaquine, they showed normal limits of hematological profile with no agranulocytosis (Molta et al, 2003).…”

Efficacy of Artemisinin-Based Combination Treatments of Uncomplicated Falciparum Malaria in Under-Five-Year-Old Nigerian Children Ten Years Following Adoption as First-Line Antimalarials

“…This finding is analogous to showing AA significantly reduced the risk of recurrent infections compared with AL in children from the same endemic areas. 21 Thus, the prophylactic efficacy of AA over AL in our previous study 21 and of DHP over AA and AL in the present study is explicable in the context of relatively long plasma terminal elimination half-lives of their partner drugs (∼10-50 days) [36][37][38][39] compared with lumefantrine in malarious patients. Our finding that DHP significantly reduced the risk of recurrent parasitemia is also similar to a previous study in falciparum malaria 16 and may be analogous to another showing prophylactic efficacy of piperaquine in vivax malaria.…”

Hematoxicity of amodiaquine in sprague-dawley rats

“…This is in consonance with previous studies[1112] that observed marginal and within normal limits of hematological profile with no agranulocytosis in patients who received AQ treatment. However, this is in contrast with other studies[3] that reported agranulocytosis in adults taking AQ for prophylaxis. The variation observed might be due to the duration of treatment, as cases that reported AQ-induced agranulocytosis were associated with its long-term use as prophylaxis.…”

Artemisinin-induced delayed hemolysis after administration of artesunate and artesunate-amodiaquine in malaria-free Wistar rats

“…Amodiaquine is implicated as a cause of neutropenia, which is characterized by a decrease in granular white blood cells after prolonged use for prophylaxis (Olliaro and Mussano, 2003). Our findings are in consonance with other reported animals studies (Omotuyi, 2008) and that observed in human treated with amodiaquine, they showed normal limits of hematological profile with no agranulocytosis (Molta et al, 2003).…”

Efficacy of Artemisinin-Based Combination Treatments of Uncomplicated Falciparum Malaria in Under-Five-Year-Old Nigerian Children Ten Years Following Adoption as First-Line Antimalarials

“…This finding is analogous to showing AA significantly reduced the risk of recurrent infections compared with AL in children from the same endemic areas. 21 Thus, the prophylactic efficacy of AA over AL in our previous study 21 and of DHP over AA and AL in the present study is explicable in the context of relatively long plasma terminal elimination half-lives of their partner drugs (∼10-50 days) [36][37][38][39] compared with lumefantrine in malarious patients. Our finding that DHP significantly reduced the risk of recurrent parasitemia is also similar to a previous study in falciparum malaria 16 and may be analogous to another showing prophylactic efficacy of piperaquine in vivax malaria.…”

Hematoxicity of amodiaquine in sprague-dawley rats

“…This is in consonance with previous studies[1112] that observed marginal and within normal limits of hematological profile with no agranulocytosis in patients who received AQ treatment. However, this is in contrast with other studies[3] that reported agranulocytosis in adults taking AQ for prophylaxis. The variation observed might be due to the duration of treatment, as cases that reported AQ-induced agranulocytosis were associated with its long-term use as prophylaxis.…”

Artemisinin-induced delayed hemolysis after administration of artesunate and artesunate-amodiaquine in malaria-free Wistar rats

“…Amodiaquine is implicated as a cause of neutropenia, which is characterized by a decrease in granular white blood cells after prolonged use for prophylaxis (Olliaro and Mussano, 2003). Our findings are in consonance with other reported animals studies (Omotuyi, 2008) and that observed in human treated with amodiaquine, they showed normal limits of hematological profile with no agranulocytosis (Molta et al, 2003).…”

Efficacy of Artemisinin-Based Combination Treatments of Uncomplicated Falciparum Malaria in Under-Five-Year-Old Nigerian Children Ten Years Following Adoption as First-Line Antimalarials

“…This finding is analogous to showing AA significantly reduced the risk of recurrent infections compared with AL in children from the same endemic areas. 21 Thus, the prophylactic efficacy of AA over AL in our previous study 21 and of DHP over AA and AL in the present study is explicable in the context of relatively long plasma terminal elimination half-lives of their partner drugs (∼10-50 days) [36][37][38][39] compared with lumefantrine in malarious patients. Our finding that DHP significantly reduced the risk of recurrent parasitemia is also similar to a previous study in falciparum malaria 16 and may be analogous to another showing prophylactic efficacy of piperaquine in vivax malaria.…”